Skip to main content
Signal8
Launch Terminal

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSAHealthcare
-5.45%$92.24
AH$92.24+0.00%vs close
Mkt Cap$7.25B
Float39.17M
O/S78.57M
Vol
$ Vol
RVOL
Inst Own56.2%
SI9.6%
Earnings
Dilution
Kiniksa Pharmaceuticals International, plc logoNASDAQ:KNSA$92.24-5.45%
Upcoming Catalysts
Phase Distribution
10 lead-sponsored trials·3 active·6 completed
Phase 11
Phase 25
Phase 2/32
Phase 31
Not applicable1
(5 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

    Rilonacept, Placebo

    Recurrent Pericarditis

    Enrollment
    86
    Start
    Jan 2019
    Primary Completion
    May 2020
    Completion
    Jun 2022
    NCT03737110
  • Phase 2/3
    Completed

    Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

    mavrilimumab

    COVID

    Enrollment
    814
    Start
    Jul 2020
    Primary Completion
    Nov 2021
    Completion
    Jan 2022
    NCT04447469
  • Phase 2/3
    Recruiting

    Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

    KPL-387, Placebo

    Pericarditis, Pericarditis Acute +1

    Enrollment
    325
    Start
    Jul 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2029est.
    NCT07010159
  • Phase 2
    Completed

    KPL-301 for Subjects With Giant Cell Arteritis

    prednisone

    Giant Cell Arteritis

    Enrollment
    70
    Start
    Sep 2018
    Primary Completion
    Aug 2020
    Completion
    Nov 2020
    NCT03827018
  • Phase 2
    Completed

    A Pilot Study of KPL-914 in Recurrent Pericarditis

    KPL-914

    Recurrent Pericarditis

    Enrollment
    26
    Start
    Jan 2018
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03980522
  • Phase 2
    Completed

    Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

    KPL-404, Placebo

    Arthritis, Rheumatoid

    Enrollment
    145
    Start
    Dec 2021
    Primary Completion
    Feb 2024
    Completion
    May 2024
    NCT05198310
  • Phase 2
    Terminated

    A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

    Abiprubart, Placebo

    Sjögrens Disease

    Enrollment
    3
    Start
    Jul 2024
    Primary Completion
    Mar 2025
    Completion
    May 2025
    NCT06531395
  • Phase 2
    Recruiting

    Transition to KPL-387 Monotherapy Dosing & Administration Study

    KPL-387

    Recurrent Pericarditis, Heart Diseases +1

    Enrollment
    120
    Start
    Mar 2026
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2029est.
    NCT07288216
  • Phase 1
    Completed

    Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

    KPL-404

    Healthy Volunteers

    Enrollment
    52
    Start
    Oct 2019
    Primary Completion
    Jan 2021
    Completion
    Mar 2021
    NCT04497662
  • Observational
    Active, not recruiting

    REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

    -

    Recurrent Pericarditis

    Enrollment
    500
    Start
    Mar 2021
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT04687358
Search ClinicalTrials.gov for “Kiniksa Pharmaceuticals International”